Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool October 4, 2010 Ryan McBride	Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool August 30, 2010 Brian Orelli	Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition?
The Motley Fool August 30, 2010 Ryan McBride	Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams.
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool December 16, 2009 Brian Orelli	No Holiday Goodwill Twixt Biogen and Facet Biogen and Facet are still at it, as their nasty takeover fight continues.
The Motley Fool December 7, 2006 Dan Caplinger	Don't Swallow the Poison Pill Corporate takeovers are often profitable for investors, so why stop them?
The Motley Fool August 3, 2010 Brian Orelli	Drama Continues: What's Genzyme Worth to Sanofi? Just get on with it, Sanofi and Genzyme. How much is Genzyme worth? Whatever its board of directors is willing to let it go for.
The Motley Fool March 29, 2005	What's a Hostile Takeover? Some companies need to look out for hostile takeovers.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
The Motley Fool April 8, 2010 Brian Orelli	Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult.
The Motley Fool August 7, 2009 Brian Orelli	A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court.
The Motley Fool June 15, 2010 Ryan McBride	Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool September 24, 2008 Brian Lawler	Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems.
BusinessWeek February 9, 2004 Kerry Cappell	This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool February 4, 2004 J. Graham	Sanofi's Aggressive for Aventis The drug company wants larger rival Aventis any way it can get it.
Chemistry World July 31, 2013 Daniel Johnson	Perrigo bags Elan and its bargain Irish tax rates US drugmaker Perrigo has agreed to buy Irish pharma company Elan in a deal worth $8.6 billion. This hands Perrigo a base in low-tax Ireland and annual savings of up to $150 million in tax and operating costs.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool July 26, 2010 Ryan McBride	How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis
The Motley Fool August 20, 2010 Brian Orelli	This Billionaire Likes Biotech. Should You? It depends on how much you trust management.
The Motley Fool May 13, 2009 Brian Orelli	Icahn's an Energizer Pit Bull He keeps going and doesn't let go.
The Motley Fool May 1, 2009 Rick Aristotle Munarriz	Sirius Poison The satellite radio giant is adopting a poison pill clause in an 8-K filing, essentially thwarting hostile takeovers by granting existing shareholders diluting rights if a potential acquirer snaps up more than 4.9% of the company's stock.
The Motley Fool August 7, 2008 Brian Orelli	The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates.
The Motley Fool September 28, 2007 Brian Lawler	Bioenvision Shareholder Battle Genzyme announces that it "cannot and will not" raise its $5.60-a-share bid for Bioenvision before shareholders go to vote on its proposed takeover. Investors, take note.
The Motley Fool September 15, 2009 Brian Orelli	What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri.
CFO June 1, 2004 Lori Calabro	Letting Down Your Guard With takeover defenses being increasingly dismantled, will a rise in hostile acquisitions be the result?
BusinessWeek November 11, 2009 Jessica Silver-Greenberg	M&A Goes Hostile Unfriendly bids are rising, and defenses are weaker.
The Motley Fool April 30, 2007 Tom Taulli	Proxy Fights 101 How shareholder skirmishes are transforming Wall Street. It's smart to understand how proxy fights work, but don't assume they're a good system for investing. Proxy battles often target struggling companies with volatile stocks.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool May 7, 2004 Bill Mann	Rash of Activism at Staples This year's proxy statement from office supply giant Staples contains four separate shareholder proposals, the first time any shareholder proposals have been made in the last ten years.
The Motley Fool January 5, 2010 Brian Orelli	Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out.
The Motley Fool May 29, 2008 Brian Lawler	Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors.
The Motley Fool April 26, 2004 J. Graham	Sanofi Finally Nabs Aventis The French drug companies make a deal to merge.
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.
The Motley Fool May 26, 2010 Brian Orelli	Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme.
The Motley Fool October 10, 2007 Brian Lawler	Bioenvision Demands a Recount Bioenvision decided to hold the polls open one more day, in hopes that some stockholders who hadn't yet participated would vote for their proposed acquisition by Genzyme.
The Motley Fool February 17, 2011 Brian Orelli	What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate.
The Motley Fool February 17, 2010 Brian Orelli	Execute Well or You're Out Genzyme needs to show investors that it can rebuild.
The Motley Fool November 12, 2010 Alyce Lomax	Welcome to Proxy Fight Club Despite their downsides, proxy wars represent an important part of shareholder rights.
The Motley Fool November 8, 2007 Brian Lawler	Let the Biogen Bidding Begin Speculation of bidding by big-pharma companies for Biogen IDEC cause the shares to rise. Investors, take note.
The Motley Fool February 9, 2006 Stephen D. Simpson	Serono: On the Block and on the Clock Will the Swiss-based biotech be able to strike a good deal for shareholders?